# PFIZER (PFIZER) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/pfizer

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹3,998.7
- Change: -0.40%
- As of: 2026-09-18
- 1D return: -0.31%
- 5D return: -2.27%
- 1M return: -18.65%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, PFIZER's technical stance is characterized by a bearish trend across daily, weekly, and monthly timeframes, with the current price of ₹4002.4 trading below key moving averages and the Supertrend indicator on all observed periods. This indicates a lack of upward momentum and suggests overhead pressure. The stock has recently formed an Outside Bar pattern on the daily chart, which can sometimes signal a potential shift in sentiment, though its immediate impact is unclear given the prevailing bearish conditions.

Nearest support is observed around ₹3986.87, approximately 0.39% below the current price, with further support at ₹3982.0. Resistance is noted at ₹4013.43, just 0.28% above the current price, followed by ₹4041.37. The stock's risk profile includes an annualized volatility of 26% and a current drawdown of -32%, highlighting the potential for significant price swings.

Key conditions to monitor include the price's ability to move above the nearest resistance level at ₹4013.43 and sustain the move. Conversely, a break below the support level at ₹3986.87 could signal further downside. The recent anomaly on September 11, 2026, which showed high participation with no clear direction, and the downward gap on September 8, 2026, warrant attention for any potential follow-through.

- The stock is trading below its daily, weekly, and monthly Supertrend indicators, indicating a bearish trend across timeframes.
- Nearest support is identified at ₹3986.87, with resistance at ₹4013.43.
- An Outside Bar pattern was observed on the daily chart on September 18, 2026.
- The stock exhibits an annualized volatility of 26% and a current drawdown of -32%.
- Watch for a sustained move above ₹4013.43 or a break below ₹3986.87 for potential trend confirmation.

- Outside Bar
- Inside Bar
- Doji

### News Context

Pfizer Limited's 75th Annual General Meeting (AGM) was held on July 28, 2026, where shareholders approved all proposed resolutions. These included the adoption of financial statements for the year ending March 31, 2026, and the declaration of a final dividend of ₹75 per equity share. The company also announced its unaudited financial results for the quarter ended June 30, 2026, reporting a total income of ₹698.01 crore and a net profit of ₹204.47 crore. These results were subject to a limited review by statutory auditors. Additionally, a special window for re-lodgement of transfer and dematerialisation of physical securities was announced, running from February 5, 2026, to February 4, 2027, for specific types of securities. A board meeting outcome was also noted on September 7, 2026, though the summary details were not provided in the evidence.

- On July 28, 2026, Pfizer Limited held its 75th AGM, passing all resolutions including the adoption of FY26 financial statements and a ₹75 per equity share final dividend.
- For the quarter ended June 30, 2026, the company reported total income of ₹698.01 crore and a net profit of ₹204.47 crore, subject to a limited review.
- A special window for re-lodgement of transfer and dematerialisation of physical securities is open from February 5, 2026, to February 4, 2027.
- A board meeting outcome was filed on September 7, 2026.

- Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026. |SUBJECT: Outcome of Board Meeting

### What Changed

As of September 18, 2026, Pfizer's stock price has seen a slight decrease, closing at ₹4002.4 compared to its previous price of ₹4014.8. The available evidence does not indicate any new filings or news developments for the company. The company continues to be listed on the NSE.

- Stock price on September 18, 2026: ₹4002.4.
- Previous stock price: ₹4014.8.
- No new filings or news reported as of September 18, 2026.
- Company remains listed on the NSE.

### Official Filings

Pfizer Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, reporting a total income of ₹698.01 crore and a net profit of ₹204.47 crore. These results were subject to a limited review by statutory auditors, B S R & Co. LLP, with no modifications noted. The company also announced a final dividend of ₹75 per equity share, which was approved at the 75th Annual General Meeting held on July 28, 2026. In a management change, Mr. Amit Agarwal resigned as Executive Director – Finance & Chief Financial Officer, effective October 8, 2026. Additionally, the company is offering a special window for the re-lodgement of transfer and dematerialisation of physical securities from February 5, 2026, to February 4, 2027, for specific transactions.

- On July 28, 2026, the company reported unaudited financial results for the quarter ended June 30, 2026, with total income of ₹698.01 crore and net profit of ₹204.47 crore.
- A final dividend of ₹75 per equity share was declared and approved at the 75th Annual General Meeting on July 28, 2026.
- Mr. Amit Agarwal resigned as Executive Director – Finance & Chief Financial Officer, effective October 8, 2026.
- A special window for re-lodgement of transfer and dematerialisation of physical securities is open from February 5, 2026, to February 4, 2027.

- Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026. |SUBJECT: Outcome of Board Meeting

### Fundamentals

Pfizer's reported results show a generally positive operating trajectory. Revenue from operations has seen an increase from ₹645.03 crore in Q3 FY2025-26 to ₹653.17 crore in Q1 FY2026-27. This top-line growth has been accompanied by an improvement in profitability. Profit Before Exceptional Items And Tax rose from ₹250.15 crore in Q3 FY2025-26 to ₹276.68 crore in Q1 FY2026-27. The company's net profit, Profit Loss For Period, also followed this upward trend, increasing from ₹141.84 crore in Q3 FY2025-26 to ₹204.47 crore in Q1 FY2026-27. While expenses have also risen, the growth in revenue appears to be outpacing expense increases, contributing to improved profit margins. Finance costs have remained relatively low and stable across the reported periods.

Key monitoring areas for Pfizer would include the sustainability of revenue growth and the continued management of expenses to maintain or improve profit margins. Investors may also wish to track any significant changes in exceptional items or tax provisions that could impact the final profit for the period.

- Revenue from operations increased to ₹653.17 crore in Q1 FY2026-27 from ₹645.03 crore in Q3 FY2025-26.
- Profit Before Exceptional Items And Tax grew to ₹276.68 crore in Q1 FY2026-27, up from ₹250.15 crore in Q3 FY2025-26.
- Profit Loss For Period rose to ₹204.47 crore in Q1 FY2026-27, compared to ₹141.84 crore in Q3 FY2025-26.
- Finance costs remained below ₹2.11 crore in all reported quarters.
- Expenses increased to ₹421.33 crore in Q1 FY2026-27 from ₹433.09 crore in Q3 FY2025-26.

### Bull Case

As of September 18, 2026, Pfizer's stock is trading at ₹4002.4. While the daily and monthly technical trends indicate a bearish sentiment with Supertrend values above the closing price (₹4319.89 daily, ₹6078.81 monthly), and moving averages like the 20-day EMA (₹4369.06) and 50-day EMA (₹4556.14) are also above the current price, suggesting downward momentum, the stock is currently positioned near several support levels. The nearest support is at ₹3986.87, which is approximately 0.39% below the current price. The company has experienced a drawdown of -32%, with a maximum drawdown also at -32%, indicating the extent of its recent price decline.

- The stock's closing price on September 18, 2026, was ₹4002.4.
- The nearest identified support level is ₹3986.87.
- The current drawdown is -32%, with the maximum drawdown also recorded at -32%.

### Bear Case

The company's stock is exhibiting a bearish trend across multiple timeframes, with its current price trading below key moving averages. Technical indicators suggest a lack of strong upward momentum, and the stock has experienced significant drawdowns. This technical setup, coupled with negative returns over various periods, indicates potential headwinds.

- The daily trend analysis shows the closing price of ₹4002.4 is below the 20-day Exponential Moving Average (EMA) of ₹4369.06 and the 50-day EMA of ₹4556.14.
- The Super Trend indicator is 'bearish' on daily, weekly, and monthly timeframes, suggesting a prevailing downward price direction.
- The stock has experienced a current drawdown of -0.32, with a maximum drawdown also recorded at -0.32.
- Period returns show a decline across multiple durations, including a -0.23 return over the last year and a -0.19 return year-to-date.

### FAQs

**What was Pfizer Limited's financial performance for the quarter ended June 30, 2026?**

For the quarter ended June 30, 2026, Pfizer Limited reported a total income of ₹698.01 crore and a net profit of ₹204.47 crore. These results were subject to a limited review by statutory auditors B S R & Co. LLP, who noted no modifications.

**What dividend did Pfizer Limited declare at its 75th Annual General Meeting?**

At its 75th Annual General Meeting held on July 28, 2026, Pfizer Limited's members approved the declaration of a final dividend of ₹75 per equity share for the year ended March 31, 2026.

**What is the current technical trend for Pfizer Limited as of September 18, 2026?**

As of September 18, 2026, technical indicators suggest a bearish trend for Pfizer Limited. The daily SuperTrend indicator is at 4319.89, indicating a bearish direction. Similarly, the monthly SuperTrend is at 6078.81, also in a bearish direction, and the weekly SuperTrend is at 4794.25, confirming a bearish trend across timeframes.

**What is Pfizer Limited's recent stock performance over different periods?**

As of September 18, 2026, Pfizer Limited's stock has experienced declines over various periods. The one-year return was -0.23, the six-month return was -0.17, and the year-to-date return was -0.19. The return since the start of tracking was -0.25.

- Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026. |SUBJECT: Outcome of Board Meeting
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹4,013.43
- Risk regime: Higher Price Risk

### Support levels
- 3982
- 3865
- 3701

### Resistance levels
- 4201.049999999999
- 4356.3
- 4527.896875

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | -0.31% |
| return_10 | -13.81% |
| return_1m | -16.60% |
| return_1y | -22.92% |
| return_20 | -18.65% |
| return_3m | -11.83% |
| return_5 | -2.27% |
| return_6m | -16.93% |
| return_since_start | -24.59% |
| return_ytd | -18.58% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | high_risk |
| label | Higher price risk |
| summary | Recent drawdown or price variability is materially high and may lead to larger short-term outcomes. |
| maximum_drawdown | -32.04% |
| annualized_volatility | +25.69% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue Growth Outpaces Expense Increase, Lifts Profit

Pfizer India reported revenue from operations of ₹653.17 crore for the quarter ended 30 June 2026, an 8.3% increase from the same period last year. Total expenses rose 2.6% to ₹421.33 crore. This divergence between top-line growth and cost increases led to a 6.6% rise in net profit to ₹204.47 crore. The results place revenue and earnings near the upper end of the range observed in the non-spike quarters of the prior year, following an unusually high second quarter.

## Revenue Expansion

Revenue from operations grew 8.31% year-on-year, adding ₹50.12 crore compared to the first quarter of the previous year. On a sequential basis, revenue increased 3.80% from ₹629.23 crore in the fourth quarter of the prior year. The current quarter's revenue represents the highest level recorded outside of the exceptional second quarter spike seen previously.

## Expense Management and Margin Improvement

Total expenses increased 2.59% year-on-year to ₹421.33 crore, rising 2.72% sequentially from the prior quarter. The slower pace of expense growth relative to revenue contributed to an expansion in the operating profit margin, calculated as revenue less total expenses. This margin expanded to 35.5% from 31.9% a year ago.

Within the expense line items, other expenses declined 12.87% sequentially to ₹83.42 crore and were 2.98% lower than the ₹85.98 crore reported a year ago. Finance costs also decreased significantly, falling 55.08% year-on-year to ₹1.46 crore from ₹3.25 crore in the corresponding period last year.

## Profitability and Earnings

Profit before tax reached ₹276.68 crore, up 6.61% from the year-ago quarter and 2.92% higher than the preceding quarter. After deducting a tax expense of ₹72.21 crore, profit after tax stood at ₹204.47 crore, reflecting a 6.63% year-on-year increase. The effective tax rate remained stable at approximately 26.1%, consistent with the prior year's level. Basic earnings per share rose to ₹44.69 from ₹41.91, moving in line with the net profit growth.

## Comparison with Prior Periods

The current quarter's financial results align closely with the performance bands established in the first, third, and fourth quarters of the prior fiscal year. During those periods, revenue typically ranged between ₹603 crore and ₹645 crore, while profit before tax fluctuated between ₹192 crore and ₹269 crore. The second quarter of the prior year was a clear outlier, recording revenue of ₹1,245.39 crore and profit before tax of ₹514.90 crore. The latest quarter demonstrates a return to the standard operating scale observed in the surrounding periods.

## Key Takeaway

Pfizer India's first quarter results show revenue growing 8.3% while expenses increased only 2.6%, resulting in a wider operating margin and a 6.6% increase in net profit. The company's performance returned to the higher end of the range seen in the non-spike quarters of the previous year, confirming that the business has resumed its typical operating trajectory following the exceptional second quarter.

### Ratios

## Official filings

- 2026-09-18 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_18092026163850_Stock_Exchange_Intimation_-_Change_in_SMP-SG.pdf)
- 2026-09-18 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_245_WebXMLFile_20260918_165232733.xml)
- 2026-09-18 — Management Change: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_ROID_98580_KMP_Doc.zip)
- 2026-09-18 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_245_WebXMLFile_20260918_165450542.xml)
- 2026-09-18 — Management Change: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_ROID_98582_KMP_Doc.zip)
- 2026-09-07 — Generic Announcement: Pfizer Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_07092026112248_Stock_Exchange_Intimation_-_Outcome_of_the_Board_Meeting_07092026.pdf)
- 2026-08-04 — Generic Announcement: Pfizer Limited is publishing a notice regarding a special window for re-lodgement of transfer and dematerialisation of physical securities. This window, open from February 5, 2026, to February 4, 2027, is for securities purchased or sold before April 1, 2019, or where transfer requests were previously rejected due to documentation issues. The process requires submitting original physical share certificates and executed transfer deeds to the Registrar and Share Transfer Agent, MUFG Intime India Private Limited. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_04082026165042_Stock_Exchange_Intimation_Re_lodgement_of_trading_window.pdf)
- 2026-07-29 — Generic Announcement: Pfizer Limited's 75th Annual General Meeting was held on July 28, 2026, where all resolutions were passed by the members. The resolutions included adopting the financial statements for the year ended March 31, 2026, declaring a final dividend of Rs. 75 per equity share, re-appointing a retiring director, and ratifying the remuneration of cost accountants for the financial year ending March 31, 2027. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_29072026185750_Pfizer_Limited-Evoting_and_Scrutinizer_Report_75th_AGM_2026.pdf)
- 2026-07-28 — Generic Announcement: Pfizer Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, on July 28, 2026. The company reported total income of ₹698.01 crore and a net profit of ₹204.47 crore for the quarter. The results were subject to a limited review by statutory auditors B S R & Co. LLP, with no modifications noted. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_28072026140140_Stock_Exchange_Intimation_-Outcome_of_the_Board_Meeting_28072026_final.pdf)
- 2026-07-28 — Generic Announcement: Pfizer Limited held its 75th Annual General Meeting on July 28, 2026, from 3:00 p.m. to 5:17 p.m. IST via video conferencing. The meeting included a tribute to the late former Chairman, R.A. Shah, a presentation on the company's performance and financial highlights for the year ended March 31, 2026, and discussions on ordinary and special business items. Key agenda items included the adoption of audited financial statements, declaration of a dividend of Rs. 75 per equity share, re-appointment of director P. Rengan, and ratification of remuneration for cost accountants. Results of the e-voting were to be declared within two working days. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_28072026190613_Stock_Exchange_Intimation_-AGM_Proceedings__Covering_letter_28072026.pdf)
- 2026-07-27 — Generic Announcement: Mr. Amit Agarwal has resigned as Executive Director – Finance & Chief Financial Officer of Pfizer Limited, effective October 8, 2026, to pursue an opportunity outside the company. He will also cease to be a Director on the Board and a member of several committees effective the same date. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_27072026164241_Stock_Exchange_Intimation_-_Resignation_of_Amit_Agarwal.pdf)
- 2026-07-27 — Official Filing: Pfizer Limited reported the resignation of Amit Agarwal from his position as Executive Director and Chief Financial Officer. The effective date for these changes is October 8, 2026. This disclosure pertains to a change in management for the listed entity.
- 2026-07-20 — Official Filing: Pfizer Limited will hold a Board Meeting and an Audit Committee Meeting on July 28, 2026, to consider its unaudited standalone quarterly financial results for the period ended June 2026. The trading window for the company's securities will be closed from June 30, 2026, to July 30, 2026.
- 2026-07-17 — Generic Announcement: Pfizer Limited has temporarily discontinued Premarin Vaginal Cream in India due to supply constraints. The company is actively working to restore supply. This product contributes less than 1% to revenue and its discontinuation is not expected to materially impact financial performance, business operations, or profitability. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_17072026181213_Pfizer_reply_to_rumour_verification_sought_by_NSE.pdf)
- 2026-07-10 — Generic Announcement: Pfizer Limited has submitted a certificate dated July 10, 2026, from KFin Technologies Limited, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_10072026172439_Stock-Exchange_Intimation_-_74_5__30062026.pdf)
- 2026-07-07 — Generic Announcement: Pfizer Limited announced its 75th Annual General Meeting (AGM) will be held on July 28, 2026, via Video Conference/Other Audio-Visual Means. The company also recommended a final dividend of Rs. 75 per equity share for the financial year ended March 31, 2026, with a record date of July 17, 2026, and payment on or after August 4, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_07072026170959_SE_Intimation_Notice_of_AGM_Newspaper_Advertisement.pdf)
- 2026-07-07 — Generic Announcement: Pfizer Limited is providing shareholders whose email addresses are not registered with the company a weblink to access the Annual Report for the financial year 2025-26, in accordance with SEBI regulations. The 75th Annual General Meeting is scheduled for July 28, 2026, via video conference. The company also announced a final dividend of Rs. 75 per equity share, with a record date of July 17, 2026, and a dividend payment date on or after August 4, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_07072026171423_SE_Intimation_letter_for_weblink_of_Annual_report.pdf)
- 2026-07-06 — Generic Announcement: Pfizer Limited will hold its 75th Annual General Meeting on July 28, 2026, via Video Conferencing. The company has submitted its Annual Report for the financial year ended March 31, 2026. The Board has recommended a final dividend of Rs. 75 per equity share, subject to member approval at the AGM. Remote e-voting will be open from July 24 to July 27, 2026. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_06072026222023_Pfizer_Limited_-_AGM_notice.pdf)
- 2026-07-06 — Official Filing: Pfizer Limited will hold its 75th Annual General Meeting on Tuesday, July 28, 2026, at 15:00:00 in Mumbai via Video Conference. The agenda includes the adoption of financial statements for the year ended March 31, 2026, declaration of a final dividend, re-appointment of Mr. P. Rengan as Executive Director until October 27, 2028, and ratification of remuneration for M/s. Kishore Bhatia & Associates as Cost Auditor for the financial year ending March 31, 2027.
- 2026-06-26 — Generic Announcement: Pfizer Limited will close its trading window from June 30, 2026, for the declaration of unaudited financial results for the quarter ending June 30, 2026. The window will reopen 48 hours after the financial results are publicly announced. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_26062026104707_Stock-Exchange_Intimation_Closure_of_Trading_Window_30062026.pdf)
- 2026-06-04 — Generic Announcement: Pfizer Limited will transfer unclaimed dividends and shares, where dividends have been unclaimed for seven consecutive years, to the Investor Education and Protection Fund (IEPF). Shareholders with unclaimed dividends for the financial year ended March 31, 2019, must claim them by August 31, 2026, to avoid their underlying shares being transferred to IEPF. Blue Chip Tex Industries Limited will transfer equity shares with unclaimed dividends for seven consecutive years, starting from the financial year 2018-19, to the IEPF Demat Account by October 20, 2026. Zee Media Corporation Limited has opened a special window from February 5, 2026, to February 4, 2027, for the transfer and dematerialization of physical securities sold or purchased before April 1, 2019, that were not lodged or were rejected. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_04062026170912_SE_intimation_-_IEPF_Newspaper_Advt.pdf)
- 2026-06-03 — Generic Announcement: Pfizer Limited announced a special window from February 5, 2026, to February 4, 2027, for shareholders to re-lodge transfer deeds of physical securities sold or purchased before April 1, 2019, which were previously rejected or returned due to documentation deficiencies. The re-lodged shares will be issued in demat form only, and submissions should be made to KFin Technologies Limited. — [Official attachment](https://nsearchives.nseindia.com/corporate/PFIZER_03062026150605_Stock_Exchange_Intimation_Re_lodgement_of_Special_Window_03062026.pdf)

## News and market events

- 2026-09-09 — BUSINESSTODAY: **Novartis India shares zoom 20% to hit record high; Minipress deal fuels rally** — Novartis India, Novartis India shares, Minipress, Minipress XL, Pfizer India, Pfizer shares, pharma stocks, pharmaceutical stocks, trademark acquisition, Rs 1,250 crore deal, prazosin, hypertension, BPH, stock market, NSE, BSE — [Source](https://www.businesstoday.in/markets/stocks/story/novartis-india-shares-zoom-20-to-hit-record-high-minipress-deal-fuels-rally-554176-2026-09-09)
- 2026-09-08 — BUSINESSTODAY: **Pfizer shares hit 52-week low after Minipress XL discontinuation; Novartis zooms 13%** — Pfizer shares, Pfizer Ltd, Minipress XL, Novartis India, Novartis shares, Minipress, Minipres, Pfizer stock, Novartis stock, Rs 1,250 crore deal, Rs 131.38 crore, prazosin, hypertension, benign prostatic hyperplasia, BPH, pharmaceutical stocks, pharma shares, stock market news, 52-week low, 52-week high — [Source](https://www.businesstoday.in/markets/stocks/story/pfizer-shares-hit-52-week-low-after-minipress-xl-discontinuation-novartis-zooms-13-553906-2026-09-08)
- 2026-09-07 — DECCANCHRONICLE.COM: **Maharashtra: Novartis India buys Minipress brands from Pfizer for Rs 1250 crore** — Following the approval, Novartis India signed an asset purchase agreement and trademark assignment deeds: Reports — [Source](https://www.deccanchronicle.com/nation/maharashtra-novartis-india-buys-minipress-brands-from-pfizer-for-rs-1250-crore-1985582)
- 2026-09-07 — Economic Times: **360 One Group CEO Bhagat buys 1.3 lakh shares of Novartis India for Rs 22 cr** — Karan Bhagat acquired 1.3 lakh Novartis India shares for nearly Rs 22 crore. His firm Kyrush Investments sold an equal number of shares in the transaction. Novartis India also announced acquiring trademarks from Pfizer for Rs 1,250 crore. Earlier, Novartis AG agreed to sell its stake to a consortium. This deal excluded its innovative medicines business in the country. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/360-one-group-ceo-bhagat-buys-1-3-lakh-shares-of-novartis-india-for-rs-22-cr/articleshow/133887525.cms)
- 2026-08-20 — MONEYCONTROL: **Quant MF raises Pfizer stake with Rs 131 cr purchase; Pari Washington buys over 2% in Amrutanjan Health Care** — Bulk Deals,Pfizer,Amrutanjan Health Care,Apollo Pipes,Welspun Investments and Commercials,Credent Connect N Care, — [Source](https://www.moneycontrol.com/news/business/markets/quant-mf-raises-pfizer-stake-with-rs-131-cr-purchase-pari-washington-buys-over-2-in-amrutanjan-health-care-14011816.html)
- 2026-08-20 — BUSINESS: **Volumes spurt at MMTC Ltd counter** — MMTC Ltd notched up volume of 373.46 lakh shares by 14:14 IST on NSE, a 29.12 fold spurt over two-week average daily volume of 12.82 lakh shares — [Source](https://www.business-standard.com/markets/capital-market-news/volumes-spurt-at-mmtc-ltd-counter-126082000669_1.html)
- 2026-08-17 — BUSINESS: **Global Markets Mixed Amid Geopolitical Tensions and Upcoming Economic Reports** — Stock futures show a varied start as investors monitor Middle East conflicts, retail earnings and upcoming Fed rate expectations. — [Source](https://www.business-standard.com/markets/capital-market-news/global-markets-mixed-amid-geopolitical-tensions-and-upcoming-economic-reports-126081700421_1.html)
- 2026-08-06 — Times of India: **Top stocks to buy today: Stock recommendations for August 6, 2026 - check list** — img border="0" hspace="10" align="left" style="margin-top:3px;margin-right:5px;" src="https://timesofindia.indiatimes.com/photo/132979582.cms" /Top stock market recommendations: Ambuja Cements, Asahi India Glass, and Pfizer - these stocks have been identified as the top buy calls for August 6, 2026 by Aakash K Hindocha, Vice President - Research, Nuvama Professional Clients Group/Nuvama Wealth Management. The expert has also shared outlook on Nifty50 and Bank Nifty: — [Source](https://timesofindia.indiatimes.com/business/india-business/top-stock-recommendations-for-august-06-2026-ambuja-cements-asahi-india-glass-pfizer-best-stocks-to-buy-today/articleshow/132979582.cms)
- 2026-07-29 — The Hindu: **Sensex today | Stock Market Live: Sensex jumps over 850 points, Nifty tops 24,240 as IT and consumer stocks lead rally** — Sensex, Nifty, Share Prices Live: Early stock market gains were led by IT, consumer and telecom stocks, even as global investors waited for the U.S. Federal Reserve's interest rate decision later in the day. — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-29-july-2026/article71276758.ece)
- 2026-07-29 — The Hindu: **Q1 Results Today Live: Adani Enterprises, Adani Ports, Asian Paints, Eicher Motors, Waaree Energies, Colgate, Prestige Estates, Syrma SGS Tech, Hexaware Tech, Dabur, Vedanta Oil, ACME Solar to announce Q1 results, HUL, L&T, Ambuja Cements, Suzlon, CUB, Tata Capital, Pfizer, Radico Khaitan shares in focus** — Q1 Results Today, 29th July 2026 Live Updates: Stay tuned for more from businessline — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-adani-enterprises-adani-ports-asian-paints-eicher-motors-waaree-energies-colgate-prestige-estates-syrma-sgs-tech-dabur-hexaware-tech-vedanta-oil-acme-results-29-july-2026/article71276282.ece)
- 2026-07-28 — CNBC-TV18: **Sensex Today | Stock Market LIVE Updates: Nifty finds resistance at 24,000; Brent slips below $86** — Sensex Today | Stock Market LIVE Updates: We are at the halfway mark of the day's trade, and the markets are looking to maintain the momentum while being cautious. The Nifty is trading flat with a positive bias. and is holding onto 24,000. The Nifty Bank is slightly under pressure, falling over 200 points, slumping to 57,000. Tech Mahindra, TCS and Infosys are the top gainers. — [Source](https://www.cnbctv18.com/market/stock-market-live-updates-sensex-nifty-50-expiry-today-oil-hdfc-bank-it-cipla-bel-tejas-hul-indus-lt-share-price-liveblog-19955200.htm)
- 2026-07-28 — CNBC-TV18: **Q1 Results LIVE Updates: Ambuja Cements reports earnings; Radico Khaitan net profit rises 76%** — Q1 Results LIVE Updates: Two Nifty 50 leaders, Larsen & Toubro and Hindustan Unilever (HUL) will be reporting results today along with broader market names like Ambuja Cements, Suzlon Energy, Varun Beverages, Cholamandalam, Radico Khaitan and many others. BEL, Coal India, Home First Finance, Indus Towers, Coforge and others will be reacting to their results today. Watch this space for all the LIVE earnings updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-hul-larsen-suzlon-varun-bev-bel-coal-india-netweb-ambuja-birlasoft-supreme-indus-tata-power-chemicals-share-price-liveblog-19955220.htm)
- 2026-07-28 — The Hindu: **Q1 Results 28th July Live: HUL Q1 profit dips, L&T, Ambuja Cements, Varun Beverages, Cholamandalam, Pfizer, Phoenix Mills, Radico, Tata Capital, Suzlon, Supreme Ind, Netweb Tech Q1 results today, Coforge zooms, BEL, Coal India, HUDCO in red** — Q1 Results Today, 28th July 2026 Live Updates: Find all the latest Q1 results 2026 updates of A-1 Limited, Aarnav Fashions, Abirami Financial Services, AGI Greenpac, Almondz Global Securities, Ambuja Cements, Anand Projects, Ardor International, Baba Arts, Birlasoft, Consolidated Construction Consortium, CEMPRO, Century Enka, CFL Capital Financial Services, Cholamandalam Investment and Finance, City Union Bank, DCM Shriram, Deep Industries, Dwarikesh Sugar Industries, Equitas Small Finance Bank,... — [Source](https://www.thehindubusinessline.com/markets/q1-results-today-live-updates-lampt-hindustan-unilever-vbl-cub-cholamandalam-finance-pfizer-radico-tata-capital-suzlon-ambuja-cements-netweb-tech-bel-coal-india-coforge-results-28-july-2026/article71272258.ece)
- 2026-07-22 — CNBC-TV18: **US stocks mixed at open as oil prices rise; Investors eye Alphabet, Tesla earnings** — The Dow Jones Industrial Average edged higher at the open, while the S&P 500 traded near the flatline and the Nasdaq Composite slipped. Investors are closely watching earnings from Alphabet and Tesla, along with higher oil prices and geopolitical developments. — [Source](https://www.cnbctv18.com/market/us-stock-market-today-futures-oil-prices-surge-alphabet-tesla-earnings-iran-tensions-19951605.htm)
- 2026-07-22 — The Hindu: **PT Jyothi Datta-The HinduBusinessLine** — [Source](https://www.thehindubusinessline.com/profile/author/pt-jyothi-datta-10732)
- 2026-07-21 — Mint: **Reported VRS payment as salary in ITR? Pune ITAT grants tax relief in ₹65.21 lakh case | Mint** — Pune ITAT has ruled that a ₹65.21 lakh payment received under a voluntary retirement scheme was a non-taxable capital receipt and not taxable salary or income from other sources. The tribunal also held that an incorrect claim in the ITR cannot override the true legal nature of the receipt. — [Source](https://www.livemint.com/money/personal-finance/reported-vrs-payment-as-salary-in-itr-pune-itat-grants-tax-relief-in-65-21-lakh-case-11784605489679.html)
- 2026-07-18 — Economic Times: **Employee wrongly reported Rs 65.21 lakh VRS payout in ITR, lost tax relief; ITAT Pune rules the amount is not taxable and grants him relief - The Economic Times** — Employee got Rs 65.21 lakh as VRS after company shut plant, but wrong ITR reporting led to tax dispute; ITAT Pune rules in his favour and gives him relief from tax — [Source](https://economictimes.indiatimes.com/wealth/tax/employee-wrongly-reported-rs-65-21-lakh-vrs-payout-in-itr-lost-tax-relief-itat-pune-rules-the-amount-is-not-taxable-and-grants-him-relief/articleshow/132476175.cms)

## Business profile

**Strategic vision:** Develops and markets pharmaceutical products and healthcare solutions.

### Business segments
- **Pfizer Products India Pvt Ltd (PPIPL):** A wholly-owned subsidiary involved in importing, trading, marketing, and distribution of pharmaceutical products in Oncology, Rare Diseases, and Anti-infectives.
- **Pfizer Limited:** A publicly listed entity specializing in Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology.
- **Pfizer Healthcare India Private Limited (PHIPL):** Engaged in manufacturing and allied services, operating a manufacturing unit in Vizag that caters to the export market.

### Competitive strengths
- Global network of R&D centers
- State-of-the-art manufacturing facilities

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/pfizer
Markdown representation: https://faxioms.com/stocks/pfizer?render=md